Corcept Therapeutics (CORT) Deferred Taxes (2017 - 2026)

Corcept Therapeutics has reported Deferred Taxes for 10 years, with the latest figure at $2.9 million in Q2 2026.

• Quarterly Deferred Taxes rose 116.22% year-over-year to $2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$16.3 million (up 67.75% YoY) and the FY2025 annual result came in at -$37.5 million, up 6.6% from the prior year.
• Deferred Taxes rose to $2.9 million in Q2 2026 per CORT's latest filing, from -$13.1 million in the prior quarter.
• Over five years, Deferred Taxes peaked at $9.1 million in Q3 2025 and troughed at -$17.8 million in Q2 2025.
• A 5-year average of -$8.4 million and a median of -$9.4 million in 2022 frame the typical range for Deferred Taxes.
• The sharpest annual moves came in 2022 and 2025: Deferred Taxes tumbled 678.8% in 2022, then soared 159.93% in 2025.
• Over 5 years, Deferred Taxes stood at -$4.5 million in 2022, then increased by 17.8% to -$3.7 million in 2023, then slipped by 5.07% to -$3.9 million in 2024, then tumbled by 293.52% to -$15.2 million in 2025, then surged by 118.98% to $2.9 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered $2.9 million, -$13.1 million, and -$15.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.